Related Experiment Video
Updated: Jun 6, 2026
11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
[Update on current care guidelines. Parkinson's disease].
Duodecim; Laaketieteellinen Aikakauskirja
|November 20, 2010
Summary
Parkinson's disease treatment strategies vary by patient. Early intervention with MAO-B inhibitors is possible, while dopamine agonists or levodopa are used for functional deficits, with advanced options for complex symptoms.
Area of Science:
- Neurology
- Pharmacology
Context:
- Parkinson's disease (PD) diagnosis and management.
- Varying patient conditions and functional deficits.
Purpose:
- To outline current treatment guidelines for Parkinson's disease.
- To differentiate initial treatment strategies based on patient profiles.
Summary:
- Initiate treatment with monoamine oxidase B-inhibitors (MAO-B-inhibitors) upon Parkinson's disease diagnosis, even before functional deficits appear.
- For younger patients (<75 years) with functional deficits, consider dopamine agonists or MAO-B-inhibitors; otherwise, levodopa is recommended.
- For refractory symptoms like on-off fluctuations and dyskinesias, explore surgical interventions and duodenal levodopa infusion. Targeted rehabilitation is crucial.
Impact:
- Provides a clear treatment algorithm for clinicians managing Parkinson's disease.
- Emphasizes personalized medicine approaches in PD management.
- Highlights advanced therapies for complex and advanced Parkinson's disease cases.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...